Polychlorinated biphenyls (PCBs) as well as dioxins (polychlorinated dibenzo-p-dioxins (PCDDs) and dibenzofurans (PCDFs)) are potentially hazardous compounds in the environment for human beings.
Introduction
Polychlorinated biphenyls (PCBs) are a compilation of 209 possible congeners with different chlorine substitutions.
Within the group of PCB congeners different subgroups can be defined ( Figure I ). The planar PCBs have no chlorine atom on the ortho position of the biphenyl ring structure and they resemble closely the dioxins because of their planar structure. The mono-ortho PCBs have one chlorine atom on the ortho position and the di-ortho PCBs have two chlorine atoms on the ortho position. All three kinds of PCB structures are also chlorinated in both para and at least two meta positions. Having more chlorine atoms on the ortho positions the coplanadty between the two phenyl rings is reduced and thus the toxicity of the congener.
The degree of biphenyl chlorination also alters the properties and applications of commercial mixtures. 1 After the detection of ubiquitous levels of PCBs in the environment, the production and use of these compounds were banned in the late 1970s. However, large amounts of PCBs were dumped so that land, water and especially sludge can still be highly polluted and thus form a source of contamination for animals and humans.
Polychiorinated dibenzo-p-dioxins (PCDDs) and dibenzofurans (PCDFs), summarized as dioxins, are tricyclic aromatic compounds. Since the number of chlorine atoms can vary between 1 and 8, there are potentially 75 different PCDD and 135 PCDF congeners. They are mainly formed as by-products during the combustion of municipal and hazardous waste and during the manufacturing of organochlorine chemicals. 2
Higher chlorinated PCB and dioxin congeners are more abundant in most biotic samples because they are highly lipophilic, chemically stable and accumulate in the food chain. For humans the main sources of exposure to these compounds are dairy products, meat and fish. 3 PCBs, PCDDs and PCDFs may produce a wide spectrum of toxic effects in animals and humans. 4'° In this paper we wish to answer the following questions: what are the PCB levels in maternal and cord plasma, and what are the PCB, PCDD and PCDF levels in human milk of Dutch women? Is there a decline in PCB or dioxin levels in human milk samples of the second and sixth week after delivery7 As dioxin measurements are time-consuming, expensive and require large volumes of blood (100-200 ml), we investigated if one of the more easily measurable PCB congener levels in maternal plasma could predict the PCB and dioxin exposure of the developing fetus and breast-fed infant,
This study is part of the Dutch PCB/Dioxin study, a prospective longitudinal study on possible adverse health effects of these pollutants for human beings.
Methods
The study group consisted of 418 healthy mother-infant pairs recruited between June 1990 and June 1992. Two hundred and seven pairs have been living in Rotterdam and the surrounding area, which is a highly industrialised region in the western part of the Netherlands. The other 211 pairs have been living in Groningen and the surrounding area, which is a semi-urban region in the north. Women were asked by their obstetrician or midwife to volunteer for the study. During the last month of pregnancy, mothers were visited at home for an explanation of the study protocol.
In order to establish an optimal study population, only infants born at term (37 to 42 weeks of gestation) without congenital anomalies or diseases were included. Pregnancy and delivery had to be passed without overt signs of serious illness or complications. All mothers and infants were of the Caucasian race. In order to study the effects of postnatal dioxin and PCB exposure a group of pregnant women was selected of whom 50% had the intention to breast-feed their infants and the other 50% to give formula feeding. Formula countains negligible levels of dioxins and PCBs. The mothers who breast-fed their infants (n=209) had to do so for at least 6 weeks. The bottle-fed infants (n=209) received formula milk from one batch during 7 months.
A blood sample was taken from the mothers in the last month of their pregnancy (36th to 40th week) for the measurement of PCB congener levels 2, 3', 4, 4' , 2, 2'3, 4, 4' , 2, 2', 4, 4', 5, 2', 3, 4, 4', 5, . 11 A blood sample of the umbilical cord was taken to measure the same PCB congener levels as an indication of prenatal exposure. Blood was collected in a vacuum system EDTA-tube, transported in a cooling-pall, and centrifuged within 24 hours during 15 minutes at 3000 rpm; plasma was stored at -20 °C until analysis.
In the second and sixth week after delivery, the mothers collected a 24-hour representative sample of breastmilk by collecting before each feeding as much milk as possible from both breasts with a vacuum pump. An aliquot of ten percent of each sample was pooled and stored in the refrigerator, the remainder was given to the infants in a bottle. After 24 hours the milk was stored at -20 °C until analysis.
PCB congeners in plasma were measured by gas chromatography with electron capture detection (GC-ECD). 12
Plasma was denaturated with methanol and the chlorinated biphenyl congeners were isolated from the plasma with hexane-ethyl ether. The extract was dried over sodium sulphate, concentrated and purified by chromatography over basic alumina deactivated with 10% water. The analysis was carried out on two capillary columns of different polarity. The limit of determination for the four congeners was 0.01 ng/g plasma. The recovery of the chlorinated biphenyl congeners added to the plasma before extraction and determined as described above, was > 95 %. In each series a chemical blank, and a control sample have been analysed to assure the quality.
The human milk samples were analysed for the 17 most abundant 2,3,7,8-substituted PCDD and PCDF congeners and three planar PCB congeners (3, 3', 4, 3, 3', 4, 4', , and 3,3' ,4,4' ,5,5'-hexachlorobiphenyl (PCB 169)) by gas chromatography-high-resolution mass spectrometry (GC-HRMS). ~3 Twenty-three non-planar PCB congeners (IUPAC no. 28, 52, 66, 70, 99, 101, 105, 118, 128, 137, 138, 141, 151, 153, 156, 170, 177, 180, 183, 187, 194, 195 and 202 ) N were measured by GC-ECD. 14 To express the toxic potency of the mixture of dioxins and PCBs in breastmilk samples, the international toxic equivalence factor (I-TEF) approach ~5 was used for the PCDDs and PCDFs, and the WHO 1993 approach for the PCBs. 16 A TEF value was assigned to the dioxin and dioxin-like PCB congeners which represents their relative toxic potency towards 2,3,7,8-TCDD, the most toxic dioxin congener which TEF value is one. By multiplying the concentration (pg/g milkfat) and TEF value, the toxic equivalent (TEQ) of each congener was calculated (pg TEQ/g milkfat). By adding up the TEQs of all congeners the total-TEQ value was obtained. The TEQ-sum of the 17 dioxin congeners yielded a dioxin-TEQ, the three planar PCB (77, 126, 169), three mono-ortho PCB (105, 118, 156) and two di-ortho PCB congeners (170, 180) revealed a planar, mono-ortho and di-ortho PCB-TEQ respectively. The other PCB congeners did not receive a TEF value because they have negligible dioxin-like activity. The study protocol had been approved by the medical ethical committee of the University Hospital
Rotterdam/Sophia Children's Hospital and the University of Groningen. Informed consent had been given by the parents.
Data analysis was performed by means of the statistical soft-ware package SPSS/PC. Means, medians, ranges and standard deviations are reported in terms of original distributions. Spearman rank correlation coefficients were measured between the different congener levels in plasma and human milk. A 95% interval for predicting the total-TEQ in human milk from the PCB 153 level in maternal plasma for an individual subject, was calculated after log transformation of the variables. The paired Student's t test was used to determine differences in mean PCB and dioxin levels in paired human milk samples of the second and sixth week, after log transformation.
Results
The mean, median and range of PCB 118, 138, 153 and 180 congener levels in maternal and cord plasma are summarized in Table I . Three maternal plasma samples missed, 36 cord plasma samples missed for the PCB 138, 153 and 180 analysis and 45 for the PCB 118 analysis, due to organization failure.
The mean, median, range and available TEQ values of all PCDD, PCDF and PCB congener levels in human milk samples of the second week after birth are summarized in Table II and III. Representative PCDD, PCDF and planar PCB congener levels are presented of 176 respectively 194 human milk samples and non-planar PCB congener levels of 195 samples.
Spearman rank correlation coefficients between levels of the four different non-planar PCB congeners (118, 138, 153, 180) within one biological sample such as maternal plasma, cord plasma or human milk are all highly significant and vary from 0.71 to 0.98. However, the correlation coefficients in human milk between all other PCB and dioxin congener levels vary considerably from -0.16 to 0.85. Relations between PCB and dioxin congener levels in different biological samples were also analysed. The correlation coefficients between levels of the four PCB congeners 118, 138. 153 and 180 in maternal plasma and cord plasma vary from 0.52 to 0.74. In Table IV Spearman rank correlation coefficients between these four PCB congener levels in maternal plasma and human milk are presented. The correlation coefficients are all significant, the corresponding congeners having the highest correlations. In Table V Spearman rank correlation coefficients between these four PCB congener levels in human milk and dioxin-and PCB-TEQ levels in human milk have been summarized. The correlation coefficients are highly significant. In Table VI Spearman rank correlation coefficients between these PCB congener levels in maternal plasma and dioxin-TEQ and PCB-TEQ levels in human milk are summarized. The correlation coefficients are less compared to the coefficients in Table V . In Figure II the 95% confidence interval for the regression line between the PCB 153 level in maternal plasma and the total-TEQ level in human milk is shown as well as the 95% predictive interval for the total-TEQ from the PCB 153 level for an individual subject. For instance, if the PCB 153 level in maternal plasma would be equal to the mean, 0.91 ng/g plasma, the upper limit of the 95 % predictive interval of the total-TEQ level in her breastmilk would be 100.0 pg TEQ/g fat, the lower limit 39.8 pg TEQ/g fat. Since the predictive interval is wide, it is impossible in this way to predict accurately the PCB and dioxin levels to which an individual fetus or breast-fed infant is exposed.
Paired human milk samples collected in the second and sixth week after birth were analyzed for dioxin-and PCB-TEQ levels. Results are presented in Table VII . The Student's t test for paired samples showed no significant decrease in mean dioxin-, planar PCB-or total-TEQ level over a four weeks period. However the mean monoortho and di-ortho PCB-TEQ level were significantly decreased in this period. 
Discussion
We measured 17 dioxin and 26 PCB congener levels in human milk and 4 PCB congener levels in mammal and cord plasma. The mean dioxin-TEQ level (30 pg TEQ/g fat) is elevated compared to dioxin background levels in the Scandinavian countries (20 pg TEQ/g fat), Spain (13 pg TEQ/g fat) and the United States (17 pg TEQ/g fat). However the dioxin and PCB levels found in this study are comparable to the levels in other highly industrialised, densely populated countries in Western Europe such as Belgium, The United Kingdom and the Federal Republic of Germany. t7 In the Netherlands the National Institute of Public Health and Environmental Protection (RIVM), measured PCDD, PCDF and PCB congener levels in human milk, in a WHO coordinated international study} 8 In 1983 only PCB congener levels (IUPAC no. 28, 52, 101, 118, 153, 138, 180 and 194) were measured. In 1988 both PCBs and dioxins were measured. The PCB levels tended to decrease over the 5 years period, as is the tendency all over the world. The median PCB congener levels we measured from 1990 to 1992 are somewhat higher (PCB 138 and 153) or similar (PCB 118, 180 and 194) to the results the RIVM presented over the year 1983. This may be due to differences in analytical methods.
PCB congener levels in maternal plasma are about five times higher compared to the levels in umbilical cord plasma. When expressed on a lipid base the levels are comparable tg, because PCBs are highly bound to lipids which contents in cord blood are low compared to maternal blood? °'2j
The total-TEQ value and the contribution of individual dioxin and PCB congener levels to the TEQ value, depend on the TEF values used. According to the model we used, the dioxins contribute for 46%, the planar PCBs for 24%, the mono-ortho PCBs for 23% and the di-ortho PCBs for 7% to the total-TEQ value (65.2 pg TEQ/g fat).
Although the mono-ortho and di-ortbo PCBs have low TEFs, they can contribute considerably to the total-TEQ because of their high concentrations in human milk.
Correlation coefficients between the non-planar PCB congener levels (PCB 118, 138, 153 and 180) in maternal plasma, cord plasma and human milk are quite high within one biological sample as plasma or human milk (0.71 to 0.98), as well as between different biological samples. However, correlation coefficients between other PCB and dioxin congener levels in human milk differ considerably. One explanation for this wide range in correlation coefficients could be that different congeners have different half-lives. Secondly, due to limitations of determination, levels of some congeners in plasma as well as in human milk might be less accurate. Finally, correlation coefficients between non-planar PCB levels in maternal plasma and dioxin-or PCB-TEQ levels in human milk are lower compared to the correlation coefficients between the same non-planar PCB congener levels in human milk and the TEQ levels in human milk. Levels in plasma are detected in ng/g plasma while levels in human milk are expressed as ng/g fat. However, when we correlated the PCB plasma levels with the TEQ levels in human milk on product base (ng/g milk), the correlation coefficients were lower. Since new fat is produced in the breast, plasma and milk might be different pools for PCB and dioxin congeners.
We found a decline in mono-ortho and di-ortho PCB-TEQ levels in human milk over a 4 weeks period. However, the dioxin-, planar PCB-and total-TEQ levels did not change in this period. Fiirst 22 and Nor6n ~3 did report a decline in dioxin levels over a longer period of breast-feeding.
Non-planar PCB levels in maternal plasma are relatively easy and cheap to analyse instead of dioxin and PCB levels in human milk, which are time-consuming, expensive measurements. Moreover it is easier to collect a blood sample than a 24-hour representative human milk sample which is an onerous task for the mothers who collect the milk. Our results demonstrate that non-planar PCB analysis in maternal plasma during pregnancy or even before conception can give an indication about in utero and postnatal breast-feeding exposure to PCDDs, PCDFs and PCBs, but the 95% predictive interval for an individual infant is wide.
